Thermo Fisher Scientific Inc.
TMO · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 3.28 | -1.88 | 2.23 |
| FCF Yield | 1.05% | 0.72% | 0.19% | 1.41% |
| EV / EBITDA | 79.42 | 66.11 | 83.38 | 74.29 |
| Quality | ||||
| ROIC | 1.87% | 2.00% | 1.95% | 2.42% |
| Gross Margin | 41.83% | 37.29% | 40.96% | 39.20% |
| Cash Conversion Ratio | 1.38 | 0.87 | 0.48 | 1.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.24% | -0.24% | -0.70% | -1.53% |
| Free Cash Flow Growth | 66.06% | 206.09% | -87.15% | 48.36% |
| Safety | ||||
| Net Debt / EBITDA | 12.79 | 10.95 | 11.44 | 9.38 |
| Interest Coverage | 5.60 | 4.75 | 6.07 | 5.91 |
| Efficiency | ||||
| Inventory Turnover | 1.13 | 1.22 | 1.17 | 1.39 |
| Cash Conversion Cycle | 110.57 | 117.30 | 117.28 | 100.70 |